The skeletal effects of the tyrosine kinase inhibitor nilotinib

► Nilotinib inhibits osteoblast proliferation and differentiation. ► Nilotinib inhibits osteoclastogenesis. ► Patients taking nilotinib have low bone turnover and secondary hyperparathyroidism. ► Prospective studies of the skeletal effects of nilotinib should be undertaken.